MARKED UP VERSION OF THE AMENDED CLAIMS - 0480/01221

3. A preparation as claimed in claim 1 [either of claims 1 or 2] having an active ingredient release of at lest 80% after 30 min.

4. A process for producing a preparation as claimed in claim 1 [any of claims 1 to 3], which comprises the paroxetine or one of its salts and the matrix material being mixed to give a homogeneous melt in an extruder and subsequently being shaped.

CLAIMS AS FILED - OZ 0480/01221

1. A solid or semisolid preparation of paroxetine or one of its physiologically acceptable salts in the form of a molecular dispersion of paroxetine in a pharmaceutically acceptable matrix material which comprises a completely synthetic polymer having a glass transition temperature of >90°C.
2. A preparation as claimed in claim 1, comprising paroxetine hydrochloride.
3. A preparation as claimed in claim 1 having an active ingredient release of at least 80% after 30 min.
4. A process for producing a preparation as claimed in claim 1, which comprises the paroxetine or one of its salts and the matrix material being mixed to give a homogeneous melt in an extruder and subsequently being shaped.
5. A process as claimed in claim 4 for producing a paroxetine hydrochloride preparation, wherein paroxetine is processed with ammonium chloride and the matrix materials to give a homogeneous melt.
6. A process as claimed in claim 5, wherein amorphous paroxetine or one of its physiologically acceptable salts is employed.